The offering expands upon Lonza’s experience in primary cells and endotoxin testing, combined with Sanquin’s expertise in MAT production
Lonza Bioscience has announced the the PyroCell MAT System for in vitro pyrogen testing.
The system is designed to ensure the safety of parenteral pharmaceuticals during development, manufacture and product release.
The PyroCell MAT System provides sensitive pyrogen detection without the use of experimental animals, thereby supporting sustainability objectives while helping to deliver safe products to the market.
Through a collaboration with Sanquin Reagents, Lonza’s PyroCell MAT System is comprised of pooled, cryopreserved Peripheral Blood Mononuclear Cells (PBMCs) developed specifically for use with the MAT. These cryopreserved PyroCell Kit PBMCs eliminate the need to qualify blood donors and undertake cell isolation for each single test run. With the PyroCell MAT System, the cells can be available on demand.
The PyroCell MAT System reagents can now be purchased throughout North America and Europe.
Orla Cloak, Director, Testing and Informatics Solutions, Lonza said: "Pharmaceutical and medical device industries are increasingly turning to more sustainable test methods for the accurate detection of pyrogenic contamination. In response to these market trends, we are very excited to expand our portfolio of sustainable testing solutions with the PyroCell MAT System, which will better support the customer’s needs during development and ensure product safety."